Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 ...